Skip to Content

  • Search

View Additional Section Content

GOG-0268 – A Phase III Evaluation of Temsirolimus (CCI-779) NCI Supplied Agent: (NSC 683864, IND 61010) in Combination with Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First Line therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary

Clinical Trial Categories

  • Ovarian Cancer
Hanjani Institute for Gynecologic Oncology at 215-885-0220


  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory


Schedule a Test
Request an Appointment


Clinical Trials Details